Clinical Trial Results:
A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 MG BID OF EVENAMIDE (NW-3509) IN PATIENTS WITH CHRONIC SCHIZOPHRENIA WHO ARE SYMPTOMATIC ON THEIR CURRENT SECOND-GENERATION ANTIPSYCHOTIC (ARIPIPRAZOLE, CLOZAPINE, QUETIAPINE, OLANZAPINE, PALIPERIDONE OR RISPERIDONE) MEDICATION
Summary
|
|
EudraCT number |
2020-006062-36 |
Trial protocol |
DE IT CZ ES RO HU PL EE LV |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Mar 2025
|
First version publication date |
27 Mar 2025
|
Other versions |
|
Summary report(s) |
Clinical Study Report_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.